This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Elicio Therapeutics Reports Inducement GrantsSeptember 18 at 8:00 AM | globenewswire.comElicio Therapeutics Reports 99% mKRAS-Specific T Cell Response in Phase 2 AMPLIFY-7P Trial of ELI-002 VaccineSeptember 17, 2025 | quiverquant.comQElicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P TrialSeptember 17, 2025 | globenewswire.comElicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant ...August 13, 2025 | finance.yahoo.comElicio Therapeutics Publishes Promising Phase 1 Study DataAugust 12, 2025 | msn.comElicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 dataAugust 12, 2025 | msn.comElicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage PatientsAugust 12, 2025 | globenewswire.comElicio Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comElicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 8, 2025 | finanznachrichten.deElicio Therapeutics: Q2 Earnings SnapshotAugust 8, 2025 | chron.comElicio (ELTX) Q2 Loss Beats EstimatesAugust 7, 2025 | fool.comElicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 7, 2025 | globenewswire.comElicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final AnalysisAugust 5, 2025 | globenewswire.comElicio Therapeutics Inc News (ELTX) - Investing.comJuly 19, 2025 | investing.comElicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic CancerJune 17, 2025 | globenewswire.comElicio Therapeutics Secures $10 Million Financing to Support Operations and Upcoming Clinical TrialsJune 5, 2025 | nasdaq.comElicio Therapeutics Secures $10 Million in FinancingJune 4, 2025 | globenewswire.comElicio Therapeutics: Q1 Earnings SnapshotMay 13, 2025 | sfgate.comElicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 13, 2025 | globenewswire.comElicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New HiresApril 16, 2025 | globenewswire.comElicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last yearApril 1, 2025 | markets.businessinsider.comElicio Therapeutics Inc.: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate UpdatesMarch 31, 2025 | finanznachrichten.deElicio Therapeutics Reports 2024 Financial Results and Provides Corporate UpdatesMarch 31, 2025 | globenewswire.comELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and MoreMarch 28, 2025 | nasdaq.comJonesTrading Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)March 25, 2025 | markets.businessinsider.comElicio Therapeutics Hires CFO From Cidara TherapeuticsMarch 24, 2025 | marketwatch.comElicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial OfficerMarch 24, 2025 | globenewswire.comWith 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stakeMarch 14, 2025 | finance.yahoo.comClal Biotech Completes Elicio Divestment and Initiates Loan RepaymentFebruary 12, 2025 | tipranks.comWhy Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025February 4, 2025 | msn.comElicio Shares Slide After Follow-On Offering Prices at DiscountFebruary 1, 2025 | marketwatch.comElicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 DataJanuary 31, 2025 | seekingalpha.comElicio Therapeutics prices 1.26M shares at $7.925 in registered direct offeringJanuary 31, 2025 | markets.businessinsider.comElicio Therapeutics secures $10 million in direct offeringJanuary 30, 2025 | msn.comElicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | finance.yahoo.comJonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)January 24, 2025 | markets.businessinsider.comElicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational StrategyJanuary 22, 2025 | globenewswire.comElicio Therapeutics Advances ELI-002 and Secures FundingDecember 13, 2024 | finance.yahoo.comJonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)December 13, 2024 | markets.businessinsider.comElicio Therapeutics presents updated results from ELI-002 Phase 1 studyDecember 12, 2024 | markets.businessinsider.comElicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024December 12, 2024 | globenewswire.comElicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 15, 2024 | finanznachrichten.deElicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 13, 2024 | globenewswire.comElicio Therapeutics (ELTX) Receives a Buy from JonesTradingNovember 9, 2024 | markets.businessinsider.comElicio Therapeutics presents updated preliminary results from AMPLIFY-7PNovember 7, 2024 | markets.businessinsider.comElicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingNovember 7, 2024 | globenewswire.comJones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy RecommendationNovember 2, 2024 | msn.comElicio Therapeutics initiated with a Buy at JonesResearchOctober 31, 2024 | markets.businessinsider.comElicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation SummitOctober 31, 2024 | globenewswire.comElicio Therapeutics Reports Inducement GrantsOctober 16, 2024 | globenewswire.com Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTX Media Mentions By Week ELTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELTX News Sentiment▼0.000.76▲Average Medical News Sentiment ELTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELTX Articles This Week▼31▲ELTX Articles Average Week Get the Latest News and Ratings for ELTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Elicio Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies OCS News Today DAWN News Today VIR News Today MNMD News Today KURA News Today BGM News Today TNGX News Today GOSS News Today IMTX News Today RZLT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELTX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
